Who is sponsoring NCT06896630?

NCT06896630 is sponsored by Assiut University.

What drugs are being tested in NCT06896630?

Interventions in NCT06896630: Tenofovir Disoproxil Fumarate (TDF).

What condition does NCT06896630 study?

NCT06896630 studies Tenofovir Disoproxil Fumarate, Renal Function Disorder, Chronic HBV Infection.

Is NCT06896630 still recruiting?

NCT06896630 is currently not yet recruiting. Last updated 4 April 2025.

Last reviewed 2025-04-04 · How we verify

NCT06896630

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Tenofovir (TDF) on Renal Function in Patients With Chronic Hepatitis B

Not yet recruiting Last updated 4 April 2025

What this trial tests

trial testing Tenofovir Disoproxil Fumarate (TDF) in Tenofovir Disoproxil Fumarate in 172 participants. Not yet recruiting.

Timeline

10 April 2025

Primary endpoint
1 March 2026

1 May 2026

Quick facts

Lead sponsor	Assiut University
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	172
Start date	10 April 2025
Primary completion	1 March 2026
Estimated completion	1 May 2026
Sites	1 location across Egypt

Drugs / interventions tested

Tenofovir Disoproxil Fumarate (TDF) — full drug profile →

Conditions studied

Tenofovir Disoproxil Fumarate — all drugs for Tenofovir Disoproxil Fumarate →
Renal Function Disorder — all drugs for Renal Function Disorder →
Chronic HBV Infection — all drugs for Chronic HBV Infection →

Sponsor

Assiut University

Who can join

Adults 18 to 60, any sex, with Tenofovir Disoproxil Fumarate or Renal Function Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Effect of Long-Term Use of Tenofovir (TDF) on Renal Function in Patients with Chronic Hepatitis B Over a Five-Year Period

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tenofovir Disoproxil Fumarate (TDF)

Trials testing the same drug.

NCT05550519 — A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatm · EARLY_PHASE1 · withdrawn
NCT05423106 — A Single and Multiple Ascending Dose Study of JNJ-64457744 · Phase 1 · terminated

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06896630 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 4 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06896630.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing